Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects equal or more than 6 years of age with mild, moderate or severe hemophilia A (FVIII activity: more than 5%, 1-5%, or less than 1%, respectively)~* Subjects with previous exposure to FVIII replacement therapy~* If human immunodeficiency virus (HIV) positive, documented cluster of differentiation (CD4) count more than 200/µL within 6 months of study entry~Exclusion Criteria:~* Diagnosed with any bleeding disorder in addition to hemophilia A~* Current FVIII inhibitor or history of FVIII inhibitor (defined as positive result of the reporting laboratory)~* Subject has no history of exposure to FVIII products (previously untreated patient \[PUP\])~* Subject is currently utilizing primary FVIII prophylaxis~* Subjects anticipating elective surgery that may be planned to occur in the 6 months following study entry~* Treated with immunomodulatory therapy within 30 days prior to study entry or planned use for the duration of their study participation~* Participated in another investigational drug or device study within 30 days prior to study entry or planned participation for the duration of their study participation~* Subjects with a known hypersensitivity to hamster protein~* Significant hepatic or renal impairment (alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\] \>5 x upper limit of normal \[ULN\], bilirubin \>2 mg/dL or serum creatinine \>1.25 x ULN)~* Prothrombin Time \>1.5 x ULN~* Platelet count \<80,000 / µL~* Pregnant or breastfeeding women~* Unwilling or unable to follow the terms of the protocol~* Any condition which may compromise the subject's ability to comply with and/or perform study-related activities or that poses a clinical contraindication to study participation, in the opinion of the Investigator or Sponsor

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Xyntha (Type: EXPERIMENTAL): This trial was an open-label and included assessments of safety, clinical efficacy, and Factor VIII (FVIII) recovery in Chinese subjects with hemophilia A. Subjects received on-demand treatments with Xyntha over a 6-month (calendar day) period.

Based on this trial design, predict the completion outcome and termination type (if applicable).